- Conditions
- Pulmonary Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–36
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
- Combination Product
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 7 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- IKT-001, Placebo
- Drug
- Lead sponsor
- Inhibikase Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky • Boston, Massachusetts
- Conditions
- Pulmonary Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo, Sildenafil
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Columbus, Ohio • Providence, Rhode Island
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo
- Drug
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 33 more
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- REGN13335, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- AIR001
- Drug
- Lead sponsor
- Aires Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 17
- States / cities
- La Jolla, California • Torrance, California • Aurora, Colorado + 12 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- ubenimex
- Drug
- Lead sponsor
- Eiger BioPharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 26
- States / cities
- Beverly Hills, California • La Jolla, California • Palo Alto, California + 20 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Ambrisentan
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 36 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- CXA-10
- Drug
- Lead sponsor
- Gladwin, Mark, MD
- Individual
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania